Kirsty Wai Chung Lee1, Sally Lord2, Richard S Finn3, Elgene Lim4, Andrew Martin2, Sherene Loi5, Jodi Lynch1, Michael Friedlander6, Chee Khoon Lee7,8. 1. Cancer Care Centre, St George Hospital, Sydney, NSW, Australia. 2. National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW, 1450, Australia. 3. Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA. 4. Garvan Institute of Medical Research and St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia. 5. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 6. Prince of Wales Hospital, Sydney and Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia. 7. Cancer Care Centre, St George Hospital, Sydney, NSW, Australia. chee.lee@ctc.usyd.edu.au. 8. National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW, 1450, Australia. chee.lee@ctc.usyd.edu.au.
Abstract
PURPOSE: Adding cyclin-dependent kinase (CDK) 4/6 inhibitor to endocrine therapy improves progression-free survival (PFS) in advanced breast cancer but the impact of ethnicity on efficacy and toxicity is unclear. We aimed to estimate the relative treatment efficacy and toxicity of endocrine therapy with and without CDK4/6 inhibitors, and compare between Asian/non-Asian subgroups. METHOD: This meta-analysis included published first-line randomized trials comparing CDK4/6 inhibitor-endocrine therapy versus endocrine monotherapy. Hazard ratios (HR) and 95% confidence intervals (CI) for the overall population and Asian/non-Asian subgroups were extracted. The inverse-variance-weighted method was used to pool treatment estimates of PFS. RESULTS: Four trials (N = 2499) were included. Patients received combination CDK4/6 inhibitor-endocrine therapy (N = 1441; ribociclib, [46.4%]; palbociclib, [30.8%]; or abemaciclib, [22.8%]) versus endocrine monotherapy (N = 1058). CDK4/6 inhibitor-endocrine therapy was associated with prolonged PFS compared with endocrine monotherapy (HR 0.56; 95% CI 0.50-0.62). In Asians (N = 492), PFS HR was 0.39 (95% CI 0.29-0.51, P < 0.0001). In non-Asians (N = 2007), PFS HR was 0.62 (95% CI 0.54-0.71, P < 0.0001). There was a significant treatment-by-ethnicity interaction (P = 0.002). Toxicity data by ethnic subgroup were only available from two trials (n = 1334) with no convincing evidence that the risk of toxicity between CDK4/6 inhibitor-endocrine therapy and endocrine monotherapy varied by ethnicity. CONCLUSION: Adding CDK4/6 inhibitor to endocrine therapy prolongs PFS compared to endocrine therapy alone as first-line treatment in advanced breast cancer. The magnitude of PFS benefit is ethnicity-dependent but there is no interethnic differences in relative treatment-related toxicities. These findings may assist in the design and interpretation of trials, inform economic analyses, and stimulate pharmacogenomic research.
PURPOSE: Adding cyclin-dependent kinase (CDK) 4/6 inhibitor to endocrine therapy improves progression-free survival (PFS) in advanced breast cancer but the impact of ethnicity on efficacy and toxicity is unclear. We aimed to estimate the relative treatment efficacy and toxicity of endocrine therapy with and without CDK4/6 inhibitors, and compare between Asian/non-Asian subgroups. METHOD: This meta-analysis included published first-line randomized trials comparing CDK4/6 inhibitor-endocrine therapy versus endocrine monotherapy. Hazard ratios (HR) and 95% confidence intervals (CI) for the overall population and Asian/non-Asian subgroups were extracted. The inverse-variance-weighted method was used to pool treatment estimates of PFS. RESULTS: Four trials (N = 2499) were included. Patients received combination CDK4/6 inhibitor-endocrine therapy (N = 1441; ribociclib, [46.4%]; palbociclib, [30.8%]; or abemaciclib, [22.8%]) versus endocrine monotherapy (N = 1058). CDK4/6 inhibitor-endocrine therapy was associated with prolonged PFS compared with endocrine monotherapy (HR 0.56; 95% CI 0.50-0.62). In Asians (N = 492), PFS HR was 0.39 (95% CI 0.29-0.51, P < 0.0001). In non-Asians (N = 2007), PFS HR was 0.62 (95% CI 0.54-0.71, P < 0.0001). There was a significant treatment-by-ethnicity interaction (P = 0.002). Toxicity data by ethnic subgroup were only available from two trials (n = 1334) with no convincing evidence that the risk of toxicity between CDK4/6 inhibitor-endocrine therapy and endocrine monotherapy varied by ethnicity. CONCLUSION: Adding CDK4/6 inhibitor to endocrine therapy prolongs PFS compared to endocrine therapy alone as first-line treatment in advanced breast cancer. The magnitude of PFS benefit is ethnicity-dependent but there is no interethnic differences in relative treatment-related toxicities. These findings may assist in the design and interpretation of trials, inform economic analyses, and stimulate pharmacogenomic research.
Entities:
Keywords:
Breast cancer; Cyclin-dependent kinase 4/6 inhibitor; Ethnicity; Meta-analysis
Authors: Danielle B Tometich; Kelly A Hyland; Hatem Soliman; Heather S L Jim; Laura Oswald Journal: Cancers (Basel) Date: 2020-12-08 Impact factor: 6.639
Authors: Masato Takahashi; Eriko Tokunaga; Joji Mori; Yoshinori Tanizawa; Jan-Stefan van der Walt; Tsutomu Kawaguchi; Matthew P Goetz; Masakazu Toi Journal: Breast Cancer Date: 2021-10-18 Impact factor: 4.239
Authors: Kelly A Hirko; Gabrielle Rocque; Erica Reasor; Ammanuel Taye; Alex Daly; Ramsey I Cutress; Ellen R Copson; Dae-Won Lee; Kyung-Hun Lee; Seock-Ah Im; Yeon Hee Park Journal: BMC Med Date: 2022-02-11 Impact factor: 8.775